FRANKFURT, June 9 (Reuters) - GlaxoSmithKline (GSK)
has started a trial in the United States to test an experimental
rheumatoid arthritis drug on patients suffering from pneumonia
caused by COVID-19, the British drugmaker said on Tuesday.
The company said it plans to expand trial activity to sites
in the United Kingdom, Italy, Spain, South America and Africa.
GSK, which announced plans for the trial in May, has found
that otilimab could ease the devastating effect of the virus on
the lungs but not suppress it directly.
(Reporting by Ludwig Burger
Editing by David Goodman
)